Isavuconazole sulfate
Product Description
Polpharma S.A.
-
PL
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
Specifications
Polpharma S.A.
-
PL
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
More Products from Polpharma S.A. (34)
-
Product Elagolix sodium Amorphous form
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Empagliflozin Crystalline anhydrous
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Linagliptin Mix of form A & B
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Pimavanserin tartrate Crystalline anhydrous form C
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Rivaroxaban
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Sitagliptin hydrochloride Polymorphic form III
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Enzalutamide
We provide with Anhydrous form R1
Enzalutamide is a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of c... -
Product Isavuconazole
under development -
Product Sacubitril Valsartan
Crystalline polymorphic form
Sacubitril/valsartan is the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) with NYHA class I... -
Product Ticagrelor, Form II
DISCLAIMER Each product is protected by a patent in force in Poland and is therefore developed and manufactured solely for the purpose of Regulatory Submissions or R&D purposes. This product is not offered for sale in countries where the patent is valid and the offer or sale or any relat... -
Product Acenocoumarol
Therapeutic Area: Cardiovascular systemEU DMF available Indication: Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist -
Product Acetazolamide
Therapeutic Area: Cardiovascular systemEU DMF availableUS DMF no. 10383 availableCEP available Available also in injectable form Indication: Acetazolamide decreases the pressure in the eye and is used for adjunctive treatment of glaucoma, a condition in which increased pressure in the eye can lead to ...
Polpharma S.A. resources (2)
-
News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2
This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? -
Brochure API Product List 2024
We manufacture our products by following our customers' and health authorities' most stringent requirements. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (EuDMF, CTD), and FDA (US DMF). Material and product testing is performed in line with the European and United States Pharmacopeias.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance